# US 11,433,096 B2 · Ophthalmic formulation and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,096 B2
- Document ID: US11433096B2
- Status: Granted
- Kind: B2
- Application number: 17/371,303
- Filed: 2021-07-09
- Published: 2022-01-13
- Granted: 2022-09-06
- Earliest claimed: 2020-07-09
- Applicants: Abdelhamid Muhammad AlQallawi; Sherif Abdelhamid AlQallawi
- Inventors: Abdelhamid Muhammad AlQallawi; Sherif Abdelhamid AlQallawi
- Web page: https://patentgrep.com/patent/US11433096B2

## CPC

- A61K 33/30: Zinc; Compounds thereof
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/12: for cataracts
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods and compositions for an eye drop and medication. Accordingly, the eye drop and medication have the potential for the provision of and pioneering non-surgical treatment of eye conditions.

## Claims

### Claim 1

A method of treating cataract condition, comprising: delivering therapeutically effective concentrations of a zinc compound and at least one antihistamine for the treatment of an eye condition, wherein the antihistamine is Chlorpheniramine Maleate.

### Claim 2 (depends on 1)

The method of claim 1, wherein the zinc compound is zinc sulfate at a concentration of about 0.30% in a buffered solution.

### Claim 3 (depends on 2)

The method of claim 2, Chlorpheniramine Maleate at a concentration of about 0.06% in a buffered.

### Claim 4 (depends on 2)

The method of claim 2, wherein the delivering therapeutically effective concentrations comprises a treatment time from about 7 days to about 60 days.

### Claim 5 (depends on 2)

The method of claim 2, wherein the delivering therapeutically effective concentrations comprises an effective treatment duration is between about 2 and about 60 days.

### Claim 6 (depends on 2)

The method of claim 2, wherein the subject's cataract condition improved after 1 week of delivering therapeutically effective concentrations.

### Claim 7

A method of treating posterior capsular opacification, comprising: delivering therapeutically effective concentrations of a zinc compound and at least one antihistamine for the treatment of an eye condition, wherein the antihistamine is Chlorpheniramine Maleate, and delivering therapeutically effective concentrations address surgical complications/side effects.

### Claim 8

A method of treating blindness, comprising: delivering therapeutically effective concentrations of a zinc compound and at least one antihistamine for the treatment of an eye condition, wherein the antihistamine is Chlorpheniramine Maleate, and delivering therapeutically effective concentrations to restore vision.

### Claim 9

A method of treating glaucoma, comprising: delivering therapeutically effective concentrations of a zinc compound and at least one antihistamine for the treatment of an eye condition, wherein the antihistamine is Chlorpheniramine Maleate, and delivering therapeutically effective concentrations to reduce eye pressure to treat acute and chronic glaucoma.

### Claim 10 (depends on 1)

The method of claim 1, further comprising treating an eye condition selected from the group consisting of: Cloudy/Blurred Vision, Floaters, Edema, Retinal Hemorrhage, Optic Neuritis, Conjunctivitis, Lacrimation, Retinal Detachment, and Pus.

### Claim 11 (depends on 7)

The method of claim 7, wherein the delivering therapeutically effective concentrations comprises an effective treatment duration is between about 2 and about 60 days.

### Claim 12 (depends on 8)

The method of claim 8, wherein the delivering therapeutically effective concentrations comprises an effective treatment duration is between about 2 and about 60 days.

### Claim 13 (depends on 9)

The method of claim 9, wherein the delivering therapeutically effective concentrations comprises an effective treatment duration is between about 2 and about 60 days.

### Claim 14 (depends on 10)

The method of claim 10, wherein the delivering therapeutically effective concentrations comprises an effective treatment duration is between about 2 and about 60 days.